Posted by Michael Wonder on 12 Mar 2025
Geron announces European Commission approval of Rytelo (imetelstat), a first in class telomerase inhibitor, for the treatment of adults with transfusion-dependent anaemia due to lower risk MDS
11 March 2025 - Rytelo is the first and only telomerase inhibitor approved in the US and Europe.
Geron Corporation today announced that the European Commission has granted marketing authorisation for Rytelo (imetelstat) as a monotherapy for the treatment of adult patients with transfusion-dependent anaemia due to very low, low or intermediate risk myelodysplastic syndromes without an isolated deletion 5q cytogenetic abnormality and who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.
